Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | TLR4 | O00206 | 16/20 | 0.44 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800989 | 1.00 | SELP (0.45) | SELPLGALS8TLR4LY96 | |
| SCHEMBL8431207 | 0.97 | SELP (0.43) | SELPLGALS8TLR4LY96 | |
| SCHEMBL8434745 | 0.93 | LGALS8 (0.43) | SELPLGALS8TLR4 | |
| SCHEMBL8432784 | 0.92 | SSTR5 (0.43) | SELPTLR4 | |
| SCHEMBL8436248 | 0.91 | SELP (0.39) | SELPLGALS8TLR4LY96 | |
| SCHEMBL6807622 | 0.88 | TLR4 (0.57) | SELPLGALS8TLR4LY96 | |
| SCHEMBL6800991 | 0.88 | TLR4 (0.57) | SELPLGALS8TLR4LY96 | |
| SCHEMBL6795483 | 0.88 | TLR4 (0.57) | SELPLGALS8TLR4LY96 | |
| SCHEMBL6807623 | 0.88 | TLR4 (0.57) | SELPLGALS8TLR4LY96 | |
| SCHEMBL10961054 | 0.87 | TLR4 (0.58) | SELPLGALS8TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072767-A1 | Glucopyranose derivatives and medicaments for preventing and/or treating HIV infection diseases comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-04-15 | — | — | US | disclosed |
| EP-1095653-A9 | GLUCOPYRANOSE DERIVATIVES AND PREVENTIVES AND/OR REMEDIES FOR HIV INFECTION CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1095653-A1 | GLUCOPYRANOSE DERIVATIVES AND PREVENTIVES AND/OR REMEDIES FOR HIV INFECTION CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072767-A1 | Glucopyranose derivatives and medicaments for preventing and/or treating HIV infection diseases comprising the same as an active ingredient | UGGT1, SLC5A1, G6PD | SELP 1329/4885LGALS8 84/4885TLR4 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.